

IBD INNOVATE™

NEW PRODUCT DEVELOPMENT FOR CROHN'S & COLITIS

November 13, 2018 • The New York Academy of Medicine



CROHN'S & COLITIS
FOUNDATION



Welcome to IBD INNOVATE 2018!

The Crohn's & Colitis Foundation seeks to accelerate the discovery and development of novel products with the potential to address the unmet needs of patients with IBD. In pursuit of this objective, the Foundation recently launched **IBD Ventures** to directly fund product discovery and development. Building on the launch of IBD Ventures, this inaugural conference, **IBD INNOVATE: New Product Development for Crohn's & Colitis™**, will showcase innovative product development programs in IBD. In addition, panel discussions will address challenges and opportunities for IBD product development, accelerator ecosystems, and models for patient engagement in the product development process. This event will be an exceptional networking opportunity for all stakeholders dedicated to advancing innovative products to address the critical challenges faced by IBD patients.

Location of Meeting Events

All conference programming will be held at the New York Academy of Medicine, 1216 Fifth Avenue, New York, NY 10029.

- **Presentations, panel discussion, and reception** will be held in the **Library Reading Room** on the third floor.
- **Breakfast and lunch buffet** will be served in the **Periodicals Room** on the third floor.
- **Room 21** on the second floor is available for **attendee meetings**. Meetings scheduled through the Meeting Mojo partnering app will be assigned a meeting location (numbered table) in Room 21.

1:1 Partnering and Meeting App

To view schedules, contact attendees, and book 1:1 meetings, navigate to:
<http://ibdinnovate2018.meeting-mojo.com/>

Information and Registration

<http://www.crohnscolitisfoundation.org/ibdinnovate.html>

On-site registration will be available at 20% additional expense.

Social Media

Join today's conversation on social media using hashtag #IBDInnovate

Contact

- **Program related inquiries:**
Gerard Honig, PhD, 646-943-7479 or ghonig@crohnscolitisfoundation.org
- **Sponsorship-related inquiries:**
Ashley Calabrese, 646-943-7453 or acalabrese@crohnscolitisfoundation.org

AGENDA

Please note that this program is subject to change. Crohn's & Colitis Foundation representatives Michael Osso (President & CEO) and Gerard Honig (Research Manager) will serve as MCs for the program.

Registration and Breakfast		7:30–9 a.m.
Welcome	Michael Osso, <i>President & CEO, Crohn's & Colitis Foundation</i> Caren Heller, <i>Chief Scientific Officer, Crohn's & Colitis Foundation</i>	9–9:20 a.m.
Accelerating product discovery and development in IBD: Need and opportunity	Andrés Hurtado-Lorenzo <i>Senior Director of Translational Research</i> <i>Crohn's & Colitis Foundation</i>	
Keynote: What is the future of product development in the IBD space?	Anthony Coyle, <i>CEO, Pandion Therapeutics</i>	9:20–9:45 a.m.
Plenary Session I: Presentations with Q&A		
FOLH1/GCPII inhibition for treatment of IBD	Barbara Slusher, <i>Director, Johns Hopkins Drug Discovery Program</i>	9:45–10:45 a.m.
Harnessing the power of the microbiome to suppress pro-inflammatory bacteria in Crohn's disease	Rose Szabady, <i>Associate Director of Immunology, Vedanta Biosciences</i>	
Predicting outcome to guide therapy in IBD	Paul Lyons, <i>Vice President of Platform Delivery, PredictImmune</i>	
Break		10:45–11 a.m.

Plenary Session II: Presentations with Q&A

SonarMD, A care management platform for patients with IBD	Lawrence R. Kosinski, <i>Vice President and Chief Medical Officer, SonarMD</i>	11 a.m.–12:30 p.m.
An inflammation-targeting and responsive tacrolimus formulation for the treatment of IBD	Gregory Zugates, <i>VP Research and Development, Alivio Therapeutics, an affiliate of PureTech Health</i>	
The TLR9 receptor agonist cobitolimod: A late-stage drug candidate with a novel mode of action for the treatment of UC patients	Thomas Knittel, <i>Chief Medical Officer and Pernilla Sandwall, COO, InDex Pharmaceuticals</i>	
Abdominal vagal neuromodulation for the treatment of IBD	James Fallon, <i>Research Director, Bionics Institute</i>	
Inhibition of Serpine-1 as novel therapeutic strategy in IBD	Ron Dolle, <i>Director, Center for Drug Discovery, Washington University</i>	
Development of phage therapy for treatment of IBD	Assaf Oron, <i>Chief Business Officer, BiomX</i>	

Lunch Served

12:30–1:30 p.m.

Speed Dating

1–1:30 p.m.

Panel Discussion I: Accelerating IBD Product Development

1:30–2:45 p.m.

Discuss and address barriers and success factors for IBD product development with experts in preclinical development, clinical development, regulatory strategy, and reimbursement.

- Anthony Slavin, *Director, Immunology Pharmacology, AbbVie Bioresearch Center (moderator)*
- Richard Migliori, *Chief Medical Officer, UnitedHealth Group*
- Paul Scholl, *Independent, Former Executive Director of Immunology, Boehringer Ingelheim*
- John de Csepel, *Vice President of Medical Affairs, Medtronic*
- Anthony Coyle, *CEO, Pandion Therapeutics*

Break

2:45–3 p.m.

Panel Discussion II: Patient Engagement in Product R&D: Opportunity and Value

3–4 p.m.

Including patients and professionals with experience in patient-centered research, inclusion of patient perspective in R&D evaluation, and bioethics.

- Karin Denoyer, *CEO and Founder, Lyfebulb (moderator)*
- Inmaculada de Melo-Martin, *Professor of Medical Ethics, Weill Cornell Medicine*
- Joel Beetsch, *Vice President, Global Patient Advocacy, Celgene Corporation*
- Jen Horonjeff, *CEO and Founder, Savvy Cooperative*
- Nancy Stoll, *Independent*

Panel Discussion III: Accelerator Ecosystem

4–5:15 p.m.

Including professionals with experience working with accelerators in different settings: Academia, pharma, academic-industry collaborations, stand-alone organizations, venture capital, and foundations.

- Caren Heller, *CSO, Crohn's & Colitis Foundation (moderator)*
- Andrés Hurtado-Lorenzo, *Senior Director, Crohn's & Colitis Foundation*
- Ron Dolle, *Director, Center for Drug Discovery, Washington University*
- Kaushik Ghosal, *Director of Business Development, BioMotiv*
- Ryan Brady, *EVP of Business Development & Head of US Operations, Evotec*
- Noga Leviner, *CEO & Founder, Picnic Health*
- Tom Shehab, *Managing Partner, Arboretum Ventures*

Acknowledgements and Outlook

5:15–5:20 p.m.

Reception and Poster Session

5:20–7:30 p.m.

POSTER SESSIONS

Poster location	Poster title	Presenting Organization	Category
1	Predicting therapeutic responses in IBD using patient explants	Beth Israel Deaconess Medical Center and Harvard Medical School	Biologics, peptides, and microbiome therapeutics
2	A novel encapsulated oral formulation of all-trans retinoic acid delivers drug directly to the gut, ameliorates disease in the CD4+ CD25- adoptive cell transfer model of inflammatory bowel disease and may reduce fibrosis	TherapyXinc	Biologics, peptides, and microbiome therapeutics
3	Toward cannabis-based therapeutics for IBD treatment	Molecular Infusions	Natural products and nutrition
4	Topical thermosensitive gel formulation to improve patient comfort and efficacy in ulcerative colitis: early clinical experience	Intact Therapeutics	Devices
5	Ultrasound-mediated topical therapy utilizing novel therapeutics	Suono Bio	Devices
6	The perfect fit: Custom 3D-printed ostomy wafers	Tripp Designs	Devices
7	Novel tracking of disease activity through a home toilet	Toi Labs	Devices
8	Reprogramming probiotics to limit inflammatory bowel diseases	Rockefeller University	Biologics, peptides, and microbiome therapeutics
9	Evaluation of Camligo (alicaforsen enema) in orphan-designated pouchitis: Using digital media to support traditional patient recruitment processes	Atlantic Pharmaceuticals	Biologics, peptides, and microbiome therapeutics
10	TBA	Complete Start	Natural products and nutrition
11	Complement activation, a novel potential proposal in Crohn's and other autoimmune diseases: D-fagomine	Paleo Biotech	Natural products and nutrition
12	Microactive Plus curcumin for dietary management of IBD	Well Sciences	Natural products and nutrition

POSTER SESSIONS

Poster location	Poster title	Presenting Organization	Category
13	Nanotechnological delivery of peptides to treat serious inflammatory diseases	Bridge Biotec	Biologics, peptides, and microbiome therapeutics
14	RepliGut: An advanced adult human stem cell screening platform for the pharmaceutical and biotechnology industries	Altis Biosystems	Research tools and services
15	Discovery of gut microbiome biomarkers using NGS	Genewiz	Research tools and services
16	Developing therapeutics to support the mucosal barrier in IBD via progenitor cell modulation	Frequency Therapeutics	Small molecules
17	Brilacidin for inflammatory bowel disease: A novel, non-corticosteroid, non-biologic drug candidate in clinical development	Innovation Pharmaceuticals	Small molecules
18	Eltanexor rapidly decreases inflammation and improves outcomes in a DSS model of IBD	KaryoPharm	Small molecules
19	Selective BET bromodomain inhibition blocks Th17 cell differentiation and ameliorates colitis in mice	Parkside Scientific	Small molecules
20	Defining pharmacodynamic biomarkers for clinical trials of vamorolone and other anti-inflammatory drugs in pediatric inflammatory bowel disease	ReveraGen BioPharma	Small molecules
21	TP-317: A new approach to promote inflammation resolution and mucosal healing in inflammatory bowel disease	Thetis Pharmaceuticals	Small molecules
23	Regulora: A digital therapeutic for IBD patients with IBS	metaMe Health	Software and healthtech
24	Patient engagement and disease management platform to enable personalized treatment	Oshi Health	Software and healthtech
25	Pling: A personalized and digital educational application for recently diagnosed, pediatric IBD patients	The Techno Creatives	Software and healthtech

This conference is sponsored, in part, by:



About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

INFLAMMATORY BOWEL DISEASES®

Inflammatory Bowel Diseases® is the Official Journal of the Crohn's & Colitis Foundation. Each issue contains cutting-edge, original basic science and clinical articles about diagnosis, treatment, and management of IBD from clinicians and researchers around the world. Coverage includes articles highlighting the unique and important issues in adult and pediatric IBD.

The Journal averages 25,000 full-text online views per month, and reaches a geographically diverse audience. Interested in submitting your research? Visit www.ibdjournal.org for author guidelines and more information.



Our mission: To cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.

CROHN'S & COLITIS FOUNDATION

733 Third Avenue, Suite 510, New York, NY 10017
www.crohnscolitisfoundation.org • 800-932-2423